Relapsed and/or refractory multiple myeloma (RRMM)

Clinical trials for Relapsed and/or refractory multiple myeloma (RRMM) explained in plain language.

Never miss a new study

Get alerted when new Relapsed and/or refractory multiple myeloma (RRMM) trials appear

Sign up with your email to follow new studies for Relapsed and/or refractory multiple myeloma (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 2 Not yet finished but already full! 1

New drug cocktail targets Hard-to-Treat myeloma

Disease control Paused

This study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…

Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Sep 20, 2026 00:00 UTC

Relapsed and/or refractory multiple myeloma (RRMM)

Get alerted when new Relapsed and/or refractory multiple myeloma (RRMM) trials appear

New drug cocktail targets Hard-to-Treat myeloma